These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 36936932)
1. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Liang L; Wang X; Huang S; Chen Y; Zhang P; Li L; Cui Y Front Immunol; 2023; 14():1046771. PubMed ID: 36936932 [TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
3. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482 [TBL] [Abstract][Full Text] [Related]
4. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296 [TBL] [Abstract][Full Text] [Related]
5. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878 [TBL] [Abstract][Full Text] [Related]
6. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma. Zhao M; Huang H; He F; Fu X Front Immunol; 2023; 14():1188277. PubMed ID: 37275909 [TBL] [Abstract][Full Text] [Related]
7. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Zhu Y; Qin LX Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874 [TBL] [Abstract][Full Text] [Related]
8. Recent developments with immunotherapy for hepatocellular carcinoma. Waidmann O Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439 [TBL] [Abstract][Full Text] [Related]
9. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Sukowati C; Cabral LKD; Tiribelli C Ann Hepatol; 2022; 27(5):100740. PubMed ID: 35809835 [TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. Meng M; Li W; Yang X; Huang G; Wei Z; Ni Y; Han X; Wang J; Ye X J Cancer Res Ther; 2020; 16(2):327-334. PubMed ID: 32474520 [TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of hepatocellular carcinoma. Ayoub WS; Jones PD; Yang JD; Martin P Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526 [TBL] [Abstract][Full Text] [Related]
13. Potentiality of immunotherapy against hepatocellular carcinoma. Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958 [TBL] [Abstract][Full Text] [Related]
14. TKIs in combination with immunotherapy for hepatocellular carcinoma. Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716 [TBL] [Abstract][Full Text] [Related]
16. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. Fu Y; Liu S; Zeng S; Shen H J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650 [TBL] [Abstract][Full Text] [Related]
17. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862 [TBL] [Abstract][Full Text] [Related]
18. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy. Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319 [TBL] [Abstract][Full Text] [Related]
19. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Zhao M; Duan X; Mi L; Shi J; Li N; Yin X; Han X; Wang J; Han G; Hou J; Yin F Future Oncol; 2022 Jun; 18(18):2269-2288. PubMed ID: 35440159 [TBL] [Abstract][Full Text] [Related]
20. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Suzuki H; Iwamoto H; Seki T; Nakamura T; Masuda A; Sakaue T; Tanaka T; Imamura Y; Niizeki T; Nakano M; Shimose S; Shirono T; Noda Y; Kamachi N; Sakai M; Morita K; Nakayama M; Yoshizumi T; Kuromatsu R; Yano H; Cao Y; Koga H; Torimura T Cancer Commun (Lond); 2023 Apr; 43(4):415-434. PubMed ID: 36825684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]